Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of BioScrip, Inc. Stockholders

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS) concerning the Company’s alleged participation in a kickback scheme.

A U.S. Department of Justice press release issued on January 8, 2014 revealed that BioScrip agreed to forfeit $15 million for the Company’s alleged participation in a kickback scheme with Novartis Pharmaceuticals Corporation related to Novartis’s product Exjade®. Furthermore, on March 31, 2015, a federal judge denied, in part, a motion to dismiss a complaint alleging that BioScrip made misleading statements pertaining to the distribution of Exjade®.

If you are a BioScrip stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at [e-mail], or telephone at [phone], Melissa Fortunato, Esq. by email at [e-mail], or telephone at [phone], or toll free at [phone], or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.